• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    2/20/24 1:21:11 PM ET
    $AGRI
    $ANTE
    $ARM
    $BCS
    Metal Fabrications
    Industrials
    Advertising
    Consumer Discretionary
    Get the next $AGRI alert in real time by email

    Shares of Fluor Corporation (NYSE:FLR) fell during Tuesday’s session following fourth-quarter results.

    Fluor posted adjusted earnings of 68 cents per share, beating market estimates of 57 cents per share. The company’s quarterly sales came in at $3.82 billion versus expectations of $4.11 billion.

    Fluor shares declined 7.7% to $38.84 on Tuesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares jumped 214% to $13.00. TRxADE HEALTH announced the sale of assets of subsidiary Trxade, Inc. to Micro Merchant Systems for $22.5 million, with potential additional $7.5 million payout.
    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) surged 203% to $0.6487. AgriFORCE was granted patent from the USPTO related to its FORCEGH+ facilities.
    • Monopar Therapeutics Inc. (NASDAQ:MNPR) shares jumped 170% to $0.9130. Monopar received clearance to proceed with first-in-human Phase 1 trial of novel radiopharmaceutical MNPR-101-Zr in advanced cancers.
    • Biofrontera Inc. (NASDAQ:BFRI) gained 125% to $1.69. Biofrontera announced restructuring of supply agreement with Biofronter AG. Biofrontera also announced a $16 million private placement.
    • Biotricity, Inc. (NASDAQ:BTCY) rose 72.7% to $1.59.
    • Shineco, Inc. (NASDAQ:SISI) shares climbed 71.8% to $2.5232 after surging more than 16% on Friday. Shineco recently announced plans for a 1-for-10 reverse stock split to regain compliance with Nasdaq minimum bid requirement.
    • SciSparc Ltd. (NASDAQ:SPRC) gained 52.7% to $5.32. SciSparc reported that as part of its ongoing collaboration with Clearmind Medicine, Clearmind filed three patent applications under the international Patent Cooperation Treaty.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares rose 37% to $12.55. WuXi Advanced Therapies announced Tuesday that the U.S. Food and Drug Administration (FDA) approved it to begin analytical testing and manufacturing of AMTAGVI for Iovance Biotherapeutics at its Philadelphia site. AMTAGVI received accelerated approval of its BLA on Feb. 16. Iovance also announced on Tuesday the pricing of an underwritten offering of 23,014,000 shares of its common stock at a price of $9.15 per share.
    • CISO Global Inc. (NASDAQ:CISO) jumped 36% to $0.1359. CISO Global announced independent valuation of over $50 million for its initial IP solutions portfolio.
    • Intuitive Machines, Inc. (NASDAQ:LUNR) surged 30% to $9.51.
    • MoneyHero Limited (NASDAQ:MNY) gained 26% to $2.6599.
    • Enviva Inc. (NYSE:EVA) shares gained 19.3% to $0.39 after falling around 12% on Friday. The Wall Street Journal recently reported that Enviva was preparing to file for bankruptcy.
    • CURO Group Holdings Corp. (NYSE:CURO) surged 19.1% to $0.28.
    • Ocugen, Inc. (NASDAQ:OCGN) gained 18% to $1.12 after jumping 27% on Friday.
    • VIZIO Holding Corp. (NYSE:VZIO) surged 14.8% to $10.94 after the company inked an agreement to be acquired by Walmart.
    • Discover Financial Services (NYSE:DFS) shares rose 12% to $13.00. Capital One Financial Corp (NYSE:COF) announced its plans to purchase Discover Financial Services, marking a pivotal $35.3 billion all-stock transaction.
    • Barclays PLC (NYSE:BCS) surged 11.7% to $8.35 after the company reported fourth-quarter financial results and announced its intention to initiate a further share buyback of up to £1 billion.
    • Qurate Retail, Inc. (NASDAQ:QRTEA) jumped 10.6% to $1.15.
    • Telephone and Data Systems, Inc. (NYSE:TDS) gained 7.7% to $15.13. The company recently reported fourth-quarter financial results and issued FY24 guidance.
    • D-Wave Quantum Inc. (NYSE:QBTS) shares gained 7.4% to $1.8692. NEC and D-Wave introduced new quantum offerings to the Australian market.

    Losers

    • RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares fell 62.6% to $9.75 as the company announced a clinical hold on studies evaluating zelnecirnon.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) shares fell 32.9% to $44.60 after jumping 114% on Friday.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) fell 24.4% to $3.8350 following fourth-quarter results.
    • Universe Pharmaceuticals INC (NASDAQ:UPC) shares fell 24% to $1.87 after gaining around 44% on Friday.
    • VirnetX Holding Corporation (NYSE:VHC) dipped 23.4% to $7.05.
    • Sientra, Inc. (NASDAQ:SIEN) fell 23.4% to $0.2330.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) declined 22% to $0.17. Better Therapeutics received FDA breakthrough device designation for digital therapeutic platform targeting advanced liver disease.
    • AirNet Technology Inc. (NASDAQ:ANTE) fell 21.5% to $0.9499.
    • Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares fell 21.2% to $7.49. Tevogen Bio recently announced an $8 million equity investment.
    • Tantech Holdings Ltd (NASDAQ:TANH) fell 20.6% to $0.7701.
    • Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares fell 20.3% to $0.6760 after gaining 42% on Friday.
    • Tenaya Therapeutics, Inc. (NASDAQ:TNYA) dipped 18% to $5.18.
    • Gaxos.ai Inc. (NASDAQ:GXAI) shares declined 17.3% to $0.5830 after surging 173% on Friday. The company announced that its gaming division will launch an AI solution for game developers and studios.
    • Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) fell 16.4% to $4.370. Evolv Technology responded to short seller misinformation.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) fell 13.3% to $2.7590.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) fell 12.7% to $700.61. Supermicro announced expansion of AI solutions portfolio.
    • FLJ Group Limited (NASDAQ:FLJ) shares tumbled 11.8% to $1.04. FLJ Group filed annual report on Form 20-F for fiscal year 2023.
    • InMode Ltd. (NASDAQ:INMD) fell 11.4% to $20.19.
    • Lichen China Limited (NASDAQ:LICN) dipped 10.8% to $1.24 after gaining around 19% on Friday.
    • Opendoor Technologies Inc. (NASDAQ:OPEN) fell 9.7% to $2.7100.
    • Arm Holdings plc (NASDAQ:ARM) fell 8.1% to $117.99.
    • The Trade Desk, Inc. (NASDAQ:TTD) fell 7.6% to $82.18.
    • Oriental Culture Holding LTD (NASDAQ:OCG) shares fell 7.4% to $1.04 after gaining 21% on Friday.
    • SSR Mining Inc. (NASDAQ:SSRM) fell 7.3% to $4.55. SSR Mining is expected to release its fourth quarter financial results on Feb. 27, 2024. The company also issued an update on ongoing rescue efforts at the Çöpler mine in Türkiye. RBC Capital analyst Michael Siperco downgraded SSR Mining from Sector Perform to Underperform and lowered the price target from $6 to $3.

     

    Now Read This: Ethereum Tops $2,900; Starknet, Filecoin Among Top Gainers

    Get the next $AGRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRI
    $ANTE
    $ARM
    $BCS

    CompanyDatePrice TargetRatingAnalyst
    The Trade Desk Inc.
    $TTD
    3/6/2026$23.00Neutral → Underperform
    Wedbush
    Barclays PLC
    $BCS
    3/5/2026Buy → Hold
    Erste Group
    SSR Mining Inc.
    $SSRM
    3/5/2026$41.00Market Perform → Outperform
    BMO Capital Markets
    SSR Mining Inc.
    $SSRM
    3/4/2026Underperform → Buy
    BofA Securities
    SSR Mining Inc.
    $SSRM
    3/4/2026Sector Perform → Outperform
    National Bank Financial
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    The Trade Desk Inc.
    $TTD
    2/26/2026$17.00Neutral → Sell
    New Street
    The Trade Desk Inc.
    $TTD
    2/26/2026$25.00Buy → Hold
    Loop Capital
    More analyst ratings

    $AGRI
    $ANTE
    $ARM
    $BCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Green Jeffrey Terry was granted 398,089 shares and bought $148,101,266 worth of Class A Common Stock (6,000,000 units at $24.68), increasing direct ownership by 154% to 655,917 units (SEC Form 4)

    4 - Trade Desk, Inc. (0001671933) (Issuer)

    3/4/26 8:27:33 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $ANTE
    $ARM
    $BCS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $ANTE
    $ARM
    $BCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Weber Kevin Daniel

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:33:07 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:31:43 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Leffler Eugene Frederick converted options into 87,500 shares, increasing direct ownership by 100% to 175,000 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:30:26 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $ANTE
    $ARM
    $BCS
    SEC Filings

    View All

    SEC Form 144 filed by Evolv Technologies Holdings Inc.

    144 - Evolv Technologies Holdings, Inc. (0001805385) (Subject)

    3/6/26 4:03:40 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    SEC Form 144 filed by The Trade Desk Inc.

    144 - Trade Desk, Inc. (0001671933) (Subject)

    3/5/26 4:56:55 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    SEC Form 10-K filed by Lexicon Pharmaceuticals Inc.

    10-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

    3/5/26 4:50:45 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $ANTE
    $ARM
    $BCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Trade Desk downgraded by Wedbush with a new price target

    Wedbush downgraded The Trade Desk from Neutral to Underperform and set a new price target of $23.00

    3/6/26 8:26:23 AM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    Barclays PLC downgraded by Erste Group

    Erste Group downgraded Barclays PLC from Buy to Hold

    3/5/26 8:27:10 AM ET
    $BCS
    Commercial Banks
    Finance

    SSR Mining upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded SSR Mining from Market Perform to Outperform and set a new price target of $41.00

    3/5/26 8:24:22 AM ET
    $SSRM
    Precious Metals
    Industrials

    $AGRI
    $ANTE
    $ARM
    $BCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Letter to Shareholders from CEO Dr. Ryan Saadi

    WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives. Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time. Base

    3/6/26 3:40:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quantum Threats Are Real. These Companies Are Building the Fix

    Issued on behalf of Quantum Secure Encryption Corp. (QSE)USA News Group News CommentaryVANCOUVER, BC, March 6, 2026 /CNW/ -- A quantum-enabled cyberattack on a single major U.S. bank could trigger between $2.0 trillion and $3.3 trillion in cascading economic damage, according to a recent report from the Citi Institute[1]. That vulnerability is accelerating a global security overhaul, with global information security spending projected to reach $244.2 billion in 2026 as post-quantum cryptography emerges among the top forces reshaping enterprise defense[2]. Companies at the forefront of this transition include QSE Corp. (CSE:QSE) (OTCQB:QSEGF) (FSE: VN8), Arqit Quantum (NASDAQ:ARQQ), IonQ (NYS

    3/6/26 11:00:00 AM ET
    $ARQQ
    $IONQ
    $QBTS
    Computer Software: Prepackaged Software
    Technology
    EDP Services

    Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

    WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential transaction with Apozeal Pharmaceutical Inc. ("Apozeal"), a pharmaceutical company focused on the development and manufacturing of high-quality, cost-effective medicines. The proposed transaction represents a strategic step in advancing Tevogen Generics, established to support domestic pharmaceutical manufacturing and enhance affordability and national supply chain resilience. If consummated, the potential acquisition of Apozeal could provide Tevogen

    3/5/26 2:50:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRI
    $ANTE
    $ARM
    $BCS
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Trade Desk Introduces the Ventura Ecosystem to Advance the Future of CTV Advertising; V and Nexxen Join as the First Collaborators

    The Ventura Ecosystem aims to unite global TV operating systems and industry partners to create a more transparent, collaborative, and revenue-optimized marketplace for CTV advertising Today, The Trade Desk's Ventura, the platform built for a fairer and more transparent streaming ecosystem, takes the next step in its vision to optimize programmatic advertising in connected TV (CTV) with the launch of the Ventura Ecosystem. The Ventura Ecosystem is an industry collaboration that brings global TV operating systems and streaming platforms together to create a more transparent and revenue‑optimized marketplace, so the industry can continue to grow and thrive. Through the Ventura Ecosystem, pa

    2/24/26 9:00:00 AM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    CISO Global Appoints Dhaval Damania as EVP of Cybersecurity & IT

    Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global's

    2/23/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    $AGRI
    $ANTE
    $ARM
    $BCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolv Technologies Holdings Inc.

    SC 13G/A - Evolv Technologies Holdings, Inc. (0001805385) (Subject)

    12/12/24 3:21:41 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $ANTE
    $ARM
    $BCS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $ANTE
    $ARM
    $BCS
    Financials

    Live finance-specific insights

    View All

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SSR Mining Announces Binding Agreement to Sell Its Ownership in the Çöpler Mine for $1.5 Billion in Cash

    SSR Mining Inc. (Nasdaq/TSX:SSRM) ("SSR Mining" or the "Company") announces that it has entered into a binding memorandum of understanding to sell its 80% ownership stake in the Çöpler mine and related properties in Türkiye (collectively, "Çöpler") for $1.5 billion (the "Purchase Price") in cash (the "Transaction"). The entire $1.5 billion cash consideration is payable on the Transaction's closing. Çöpler is being acquired by Cengiz Holding A.S. ("Cengiz Holding"), one of Türkiye's largest industrial companies with operations spanning copper, gold and aluminum mining and processing, as well as major interests in construction, energy, metallurgy and the chemicals and fertilizer industries. T

    3/4/26 7:00:00 AM ET
    $SSRM
    Precious Metals
    Industrials

    Gaxos Acquires Strategic Stake in America First Defense, Developer of Advanced Drone-Based Electronic Warfare System

    Acquisition Provides Exposure to Emerging US Defense Technologies with Multi-Sector National Security Applications Roseland, NJ, March 03, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced that it acquired a 19.99% stake in America First Defense ("AFD"), a US-based defense technology company developing next-generation drone and robotics platforms. America First Defense is an American-owned defense technology company developing next-generation security platforms across both air and ground domains. The company is focused on two high-priority categories: a detachab

    3/3/26 8:12:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology